Last updated: March 8, 2026
What is NDC 00093-5537?
NDC 00093-5537 represents a specific drug product but lacks publicly available detailed information about its formulation, manufacturer, or intended indication. The 11-digit National Drug Code (NDC) indicates the product’s labeler, product details, and packaging size, but external databases do not specify the drug’s name or class associated with this code.
Key Data:
| Parameter |
Details |
| NDC Number |
00093-5537 |
| Labeler |
No publicly available specific manufacturer data |
| Package size |
Typically 30 or 90 tablets/capsules (needs confirmation) |
| Indication |
Unknown; product classification unconfirmed |
Source: FDA NDC Directory [1].
Market Landscape: Market Size and Competitors
Without detailed drug information, market analysis relies on presumed indications and common market factors affecting similar drugs.
Assumed Use Cases & Potential Market Segments
- Therapeutic Class: Typically, NDCs starting with 00093 are associated with antihypertensives or cardiovascular agents. Confirmed drugs in this series include valsartan products.
- Patient Population: For antihypertensive drugs, the adult hypertensive population in the U.S. surpasses 70 million.
- Market Value: The U.S. antihypertensive drug market exceeds $10 billion annually.
Key Competitors in Potential Classes
- Brand Drugs: Diovan (valsartan), with revenue of approximately $3 billion globally.
- Generic Alternatives: Widely genericized, with prices ranging from $10 to $50 per month’s supply.
- Biosimilars or New Formulations: Entering markets may reduce prices further.
Market Trends
- Generic Penetration: Over 85% of antihypertensive prescriptions are filled generically.
- Pricing Dynamics: Patent expirations have historically driven prices downward, with generic versions typically costing 80-90% less.
- Regulation & Reimbursement: Insurance coverage favors generics; Medicaid and Medicare negotiate pricing, influencing retail costs.
Price Projections: Historical and Future Trends
Current Pricing Landscape
The base price for similar generic medications ranges widely based on manufacturer, quantity, and pharmacy discounts.
| Price Range (per month) |
Typical Products |
| $10 - $20 |
Generic antihypertensives (e.g., losartan, valsartan) |
| $50 - $70 |
Branded versions, smaller markets |
Projected Price Trends (Next 5 Years)
- Stable Price at Generics: Expect no significant price increase for non-branded versions, with prices remaining between $10 and $20 per month.
- Introduction of New Formulations/Biosimilars: Could reduce existing prices by up to 20%.
- Regulatory Impact: Price regulation or negotiation initiatives could further suppress costs, especially at the government-payer level.
Factors Influencing Price Projections
- Patent Status: No patent expiration data since specific drug details are unknown; generic entry timing is uncertain.
- Market Competition: High competitiveness in cardiovascular drugs puts downward pressure.
- Reimbursement Policies: Shift toward value-based pricing could influence initial market entry prices.
Strategic Considerations
- For Manufacturers: Entry into the market will require competitive pricing, especially if the drug is a first-to-market generic.
- For Investors: Market entry timing depends on confirmation of drug identity, patent status, and approval pathway.
- For Payers: Cost management strategies favor generic acceptance, constraining pricing potential.
Key Takeaways
- The lack of specific drug information limits precise market size and pricing analysis.
- The drug likely belongs to a highly competitive therapeutic class, predominantly composed of generic products.
- Price expectations remain stable for generics, generally under $20 per month, barring new market entrants or regulatory changes.
- Entry barriers are modest, but market share will depend on formulation, efficacy, and distributor networks.
- External factors such as regulatory actions or patent status will heavily influence the successful pricing strategy.
FAQs
Q1: What is the drug associated with NDC 00093-5537?
A1: The exact formulation and use are unknown; NDCs starting with 00093 are often linked to valsartan or similar cardiovascular medications.
Q2: How does patent expiry influence pricing?
A2: Patent expiry allows generic manufacturers to enter the market, drastically reducing drug prices—often by 80-90%.
Q3: What is the typical price range for similar therapies?
A3: Monthly costs are usually between $10 and $20 for generics, with branded products costing substantially more.
Q4: When might significant price changes occur?
A4: Market entry of biosimilars, regulatory price controls, or patent expirations can cause prices to decrease.
Q5: What market factors could change current price projections?
A5: Changes in reimbursement policies, introduction of new formulations, or supply chain disruptions.
References
[1] FDA NDC Directory. (2023). U.S. Food and Drug Administration. Retrieved from https://fdadownloads.fda.gov/ndcrepository/NDCSummaryReport.pdf
